DE69126563T2 - Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia - Google Patents

Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia

Info

Publication number
DE69126563T2
DE69126563T2 DE69126563T DE69126563T DE69126563T2 DE 69126563 T2 DE69126563 T2 DE 69126563T2 DE 69126563 T DE69126563 T DE 69126563T DE 69126563 T DE69126563 T DE 69126563T DE 69126563 T2 DE69126563 T2 DE 69126563T2
Authority
DE
Germany
Prior art keywords
dementia
prophylaxis
peptides
mixture
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69126563T
Other languages
English (en)
Other versions
DE69126563D1 (de
Inventor
Yutaka Tsurusawa
Makito Nishiyama
Michitaro Fujimoto
Nobuyuki Iwamoto
Hirokazu Seki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ebewe Pharma GmbH Nfg KG
Original Assignee
Ebewe Pharma GmbH Nfg KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2097207A external-priority patent/JPH03294233A/ja
Priority claimed from JP2206249A external-priority patent/JPH0491034A/ja
Application filed by Ebewe Pharma GmbH Nfg KG filed Critical Ebewe Pharma GmbH Nfg KG
Publication of DE69126563D1 publication Critical patent/DE69126563D1/de
Application granted granted Critical
Publication of DE69126563T2 publication Critical patent/DE69126563T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69126563T 1990-04-12 1991-04-11 Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia Expired - Fee Related DE69126563T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2097207A JPH03294233A (ja) 1990-04-12 1990-04-12 神経突起生成を促す方法ならびに神経突起生成剤
JP2206249A JPH0491034A (ja) 1990-08-02 1990-08-02 中枢神経保護剤

Publications (2)

Publication Number Publication Date
DE69126563D1 DE69126563D1 (de) 1997-07-24
DE69126563T2 true DE69126563T2 (de) 1998-02-05

Family

ID=26438396

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69126563T Expired - Fee Related DE69126563T2 (de) 1990-04-12 1991-04-11 Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia

Country Status (4)

Country Link
EP (1) EP0452299B1 (de)
AT (1) ATE154608T1 (de)
DE (1) DE69126563T2 (de)
ES (1) ES2104686T3 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087940C (zh) * 1994-04-26 2002-07-24 中国药品生物制品标准化研究中心 脑蛋白水解物
AU735687B2 (en) * 1997-07-28 2001-07-12 Riken Agent for protecting central nerve cells and enhancing survival thereof
EP1670417A2 (de) * 2003-10-03 2006-06-21 Pharmacia Corporation Zusammensetzungen eines cyclooxygenase-2-selektiven hemmers, die unter hypothermen bedingungen verabreicht werden, zur behandlung von ischämisch vermittelten erkrankungen oder verletzungen des zentralen nervensystems
BRPI0415939A (pt) * 2003-11-12 2007-01-02 Pharmacia & Upjohn Co Llc composições de um inibidor seletivo da ciclooxigenase-2 e um agente de modulação do fator neurotrófico para o tratamento de distúrbios mediados pelo sistema nervoso central
EP1857463A1 (de) 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Neuroprotektive Wirkungen von Peptide
PL3449931T3 (pl) 2017-08-28 2020-06-01 Ever Neuro Pharma Gmbh Zastosowanie cerebrolizyny
ES2964145T3 (es) 2020-07-13 2024-04-04 Ever Neuro Pharma Gmbh Método para producir un hidrolizado de proteína de cerebro de mamífero

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1095464B (de) * 1956-05-22 1960-12-22 Univ Tulane Verfahren zur Herstellung eines Heilmittels zur Behandlung von Schizophrenie und anderen Geisteskrankheiten
IL71440A0 (en) * 1984-04-04 1984-07-31 Univ Ramot Composition for nerve regeneration
IT1219839B (it) * 1988-02-08 1990-05-24 Fidia Farmaceutici Purificazione,caratterizazione e applicazione di un fattore neuronotrofico derivato da cervello di nammifero
JPH01308300A (ja) * 1988-01-25 1989-12-12 American Cyanamid Co ヘパリン結合性脳ミトゲン

Also Published As

Publication number Publication date
DE69126563D1 (de) 1997-07-24
ES2104686T3 (es) 1997-10-16
EP0452299A1 (de) 1991-10-16
ATE154608T1 (de) 1997-07-15
EP0452299B1 (de) 1997-06-18

Similar Documents

Publication Publication Date Title
ATE169820T1 (de) Verwendung eines bakteriziden/die permeabilität erhöhenden proteins oder von biologisch aktiven analogen davon zur herstellung eines arzneimittels zur behandlung von endotoxin- assoziierten storungen
FI103278B1 (fi) Menetelmä biologisesti aktiivisen TGF- :n kaltaisen proteiinin tuottamiseksi
IL95480A0 (en) Process for the preparation of cyclic amino acids,and intermediates
DK140996A (da) Fremgangsmåde til fremstilling af 2,3,4,5-tetraflour-6-alkyl-benzoesyreforbindelser
DE68919246T2 (de) Verfahren zur Herstellung von Aminosäuren.
ATE209215T1 (de) Protegrine
EP0552240A4 (en) New method of treating depression
ATE166881T1 (de) Verfahren zur herstellung von faktor viii
DE69126563T2 (de) Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia
HUT45564A (en) Process for producing hirudine variants
SE9300758D0 (sv) Process for the production of clavulanic acid
NO930830D0 (no) Nye beta-aminosyrederivater
ATE89728T1 (de) Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen.
DE68916760D1 (de) Verfahren zur Herstellung von Gamma-Lactonen.
ES2109530T3 (es) Derivados de acidos fenil-ciclohexano-carboxilicos heterotriciclicamente sustituidos.
DE69018275T2 (de) Peptide, deren Verwendung als Hemmer gegen Entwicklung von t-Lymphocyten und Wirksamkeit von Makrophagen und Verfahren zu deren Herstellung.
ATE86984T1 (de) Verfahren zur herstellung von 5,6-substituierten- 2,4-chinazolindiaminen und zwischenprodukten.
DE68908843D1 (de) Verfahren zur Herstellung von 4,6-Dimethyl-7-hydroxynonan-3-on.
IT1230140B (it) Derivati della serina, loro processo di preparazione e impiego in terapia umana
BG101983A (en) Substituted phenylamidines, medicamentous forms containing them and mehtod for their preparation
DE68911065T2 (de) Verfahren zur Herstellung von Streckformteilen.
FI904912A0 (fi) Menetelmä (endo)-N- /(8-metyyli-8-atsabisyklo/3.2.1/oktan-3-yyli)amino/karbonyyli -2-(syklopropyylimetoksi)bentsamidin tai sen farmaseuttisesti hyväksyttävän happoadditiosuolan valmistamiseksi
DE3853092D1 (de) Verfahren zur Herstellung von Proteinen, die nicht in Proteinen vorkommende Aminosäuren enthalten.
AU1691888A (en) Compound active in cardiovascular therapy
ATE68175T1 (de) Verfahren zur herstellung von l,l oder d,d oder racemat n6 benzyloxycarbonyl 2,6 diaminopimelinsaeuremonoamid.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee